Development of Sanofi Pasteur tetravalent dengue vaccine.

R&D Dengue Vaccine Program Head, Sanofi Pasteur, Lyon, France.
Revista do Instituto de Medicina Tropical de São Paulo (Impact Factor: 0.91). 10/2012; 54 Suppl 18:15-7. DOI: 10.1590/S0036-46652012000700007
Source: PubMed
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: An effective dengue vaccine should elicit immune responses against all four different dengue virus serotypes. This study optimized the codon usage of a gene encoding consensus dengue virus envelope protein domain III (cEDIII) with cross-neutralizing activity against four dengue virus serotypes for plant expression. Then, a plant expression vector was constructed with this gene under the control of the rice amylase 3D promoter (RAmy3D), which is a strong inducible promoter under sugar starvation conditions. The synthetic cEDIII gene was fused with the RAmy3D signal peptide and ER retention signal, SEKDEL, and was introduced into rice callus by particle bombardment-mediated transformation. The integration and expression of cEDIII gene in transgenic rice callus was confirmed by genomic DNA PCR amplification, Northern blot analysis, and western blot analysis, respectively. Densitometric analysis determined that the highest expression level of the cEDIII protein in lyophilized rice callus was approximately 0.45 mg g−1. These results suggest that it is feasible to use transgenic rice callus to produce the consensus dengue virus envelop protein domain III for edible vaccine purposes.
    Plant Cell Tissue and Organ Culture 06/2012; 109(3). DOI:10.1007/s11240-012-0116-y · 2.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The Asia Pacific Pediatric Association Vaccinology Update 2010 (APPA VU 2010) was held in Mumbai on November 13-14, 2010. This second part of the conference report discusses the interesting information about vaccines which are expected in the near future, namely, live-attenuated Japanese encephalitis virus vaccine, tetravalent dengue virus vaccine, conjugate typhoid vaccine and conjugate meningococcal A vaccine.
    The Indian Journal of Pediatrics 03/2011; 78(8):993-5. DOI:10.1007/s12098-011-0385-1 · 0.92 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Dengue is an emerging infectious disease that has become the most important arboviral infection worldwide. There are four serotypes of dengue virus, DENV-1, DENV-2, DENV-3, and DENV-4, each capable of causing the full spectrum of disease. rDEN1Δ30 is a live attenuated investigational vaccine for the prevention of DENV-1 illness and is also a component of an investigational tetravalent DENV vaccine currently in Phase I evaluation. A single subcutaneous dose of rDEN1Δ30 was previously shown to be safe and immunogenic in healthy adults. In the current randomized placebo-controlled trial, 60 healthy flavivirus-naive adults were randomized to receive 2 doses of rDEN1Δ30 (N = 50) or placebo (N = 10), either on study days 0 and 120 (cohort 1) or 0 and 180 (cohort 2). We sought to evaluate the safety and immunogenicity of this candidate vaccine in 50 additional vaccinees and to test whether the humoral immune response could be boosted by a second dose administered 4 or 6 months after the first dose. The first dose of vaccine was well tolerated, infected 47/50 vaccinees and induced seroconversion in 46/50 vaccinees. Irrespective of dosing interval, the second dose of vaccine was also well tolerated but did not induce any detectable viremia or ≥4-fold rise in serum neutralizing antibody titer.Only five subjects had an anamnestic antibody response detectable by ELISA following a second dose of vaccine, demonstrating that the vaccine induced sterilizing humoral immunity in most vaccinees for at least six months following primary vaccination.The promising safety and immunogenicity profile of this vaccine confirms its suitability for inclusion in a tetravalent dengue vaccine.
    PLoS Neglected Tropical Diseases 08/2011; 5(8):e1267. DOI:10.1371/journal.pntd.0001267 · 4.49 Impact Factor
Show more


Available from